As a Contract Development & Manufacturing Organization (CDMO) focused on peptide- and oligonucleotide-based therapies, we serve pharma and biotech customers around the globe. For them we develop and manufacture the active ingredients for therapies that range from the treatment of wide-spread metabolic diseases like diabetes or obesity to cancer and cardiovascular or neurological disorders. Our mission is to help our customers secure regulatory approvals and to successfully launch and commercialize their products in the market. We are proud of having been contributing to the health of millions of patients around the world for over 70 years.

Why PolyPeptide?

Since 1952, when we started the production of commercial peptides in Malmö, Sweden, we have accumulated deep technical experience by manufacturing over 1000 peptides in GMP quality (good manufacturing practices). Today we are a focused manufacturer of peptide-based active pharmaceutical ingredients (API), operating in Europe, the US and India. In 2021, we added the manufacturing of oligonucleotides API to our range of products. We strive to maintain a close partnership with our customers, supporting them over many years along the entire drug development process. Over the years, we built a broad pipeline of active custom projects. With the expected dynamics emerging from this pipeline, we are investing to expand our capacities.

Values and aspiration

With our core values of “Innovation,” “Excellence” and “Trust,” we aim to be the preferred partner for our customers, who typically expect from their CDMO deep operational experience and scientific knowledge, coupled with a relentless focus on quality and a high delivery performance. As a multinational company with 1,273 employees at the end of 2023, we foster an agile, open and collaborative work environment. We continuously develop our organization and share best practices across the Group. Attracting and retaining qualified and engaged talent is essential for  us to implement our integrated strategy.